<DOC>
	<DOCNO>NCT02440568</DOCNO>
	<brief_summary>This dose escalation study evaluate Omacetaxine give combination standard induction regimen `` 7+3 '' ( cytarabine Days 1-7 Idarubicin Days 1-3 ) patient newly diagnose acute myelogenous leukemia ( AML ) .</brief_summary>
	<brief_title>AML-02 : Omacetaxine With Standard-of-Care Induction With Cytarabine &amp; Idarubicin Newly-Diagnosed AML Patients</brief_title>
	<detailed_description>This dose escalation study evaluate Omacetaxine give combination standard induction regimen `` 7+3 '' ( cytarabine Days 1-7 Idarubicin Days 1-3 ) patient newly diagnose acute myelogenous leukemia ( AML ) . Omacetaxine give subcutaneously Q12 hour Days 1-7 . The optimally safe active dose ( OD ) determine use EffTox design . EffTox Bayesian adaptive design seek determine optimal dose study Phase II consider trade-off efficacy toxicity . The EffTox design begin treat cohort three patient dose level 1 . These patient ' efficacy toxicity outcome use update posterior distribution probability efficacy toxicity identify acceptable dose level . The study terminate dose level acceptable . Otherwise , acceptable dos rank use Euclidean distance ( 1.0 , 0.0 ) next cohort treat dose minimum distance restriction may escalate deescalate one dose level time ( e.g. , second cohort escalate dose level 2 deescalate dose level -1 ) . The second cohort treat dose minimum distance posterior distribution , list acceptable dos distance update . This process continue least 20 subject enrol study . The dose minimum distance study completion consider optimal dose investigation . If none dose level acceptable study completion , optimal dose level identify drug warrant investigation . Post induction therapy consist standard cytarabine consolidation chemotherapy allogeneic stem cell transplantation base pretreatment risk assessment .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Newly diagnose , untreated patient AML accord WHO classification AML.18 2 . Patients age 18 70 year old meet diagnostic criterion AML accord WHO classification AML . 3 . Previously untreated AML ( ≥20 % blast ) . Note prior shortterm therapy ( ≤7 day ) hydroxyurea , steroid , biological target therapy ( e.g . FLT3 inhibitor , kinase inhibitor , azacitidine , ATRA ) , hematopoietic growth factor allow . A single twoday dose cytarabine ( 3 g/m2 ) emergency use also allow prior therapy . 4 . ECOG performance status 03 5 . Adequate organ function , suspect due AML , within 14 day study registration , define : Total bilirubin &lt; 2.0 x ULN ( unless due hemolysis ) AST ALT &lt; 3 X ULN ( unless believe due tumor involvement ) Serum Creatinine ≤ 1.5 x ULN Creatinine Clearance &gt; 30 ml/min 6 . Negative urine serum pregnancy test female . Patients reproductive potential ( male female ) must consent practice doublebarrier method contraception treatment 12 week follow last dose Omacetaxine . 7 . Patients must willing able provide inform consent 1 . Patients AML age 71 old . 2 . Acute promyelocytic leukemia . 3 . Other investigational drug use within 4 week study entry . 4 . Cardiac insufficiency grade III IV New York Heart Association ( NYHA ) 5 . Female subject pregnant breast feeding . 6 . Patients HIV positive . 7 . Active uncontrolled infection severe systemic infection 8 . Concurrent malignancy ( AML ) estimate life expectancy less two year require active therapy . 9 . Psychological , familial , sociological , geographical condition would preclude study compliance followup . 10 . Uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia medically relevant active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . 11 . Other severe acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make patient inappropriate enrollment study . 12 . Pregnant breastfeeding : Omacetaxine Pregnancy Category D medication cause embryofetal death animal . Confirmation subject pregnant must establish negative urine human chorionic gonadotropin pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>